Zimmer Partners’s Keros Therapeutics KROS Stock Holding History

Zimmer Partners’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-15,889	Closed	-$596K	–	141
2020 Q2	$596K	Buy	+15,889	New	+$490K	0.01%	99

Other funds holding KROS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Zimmer Partners's KROS Position: Q3 2020 in Review

Zimmer Partners sold out of Keros Therapeutics (KROS) in Q3 2020, closing a stake of 15,889 shares — an estimated $596K sold.

Zimmer Partners first reported a position in KROS in Q2 2020 and held it in 1 quarter. The position peaked at $596K in Q2 2020. 49 funds tracked by Wall St. Rank hold KROS as of Q3 2020.

Zimmer Partners reported no remaining Keros Therapeutics position as of Q3 2020 after selling out during the quarter.
Zimmer Partners sold 15,889 Keros Therapeutics shares in Q3 2020, an estimated $596K.
Zimmer Partners first reported a position in Keros Therapeutics in Q2 2020 and held it in 1 quarter.
Zimmer Partners's Keros Therapeutics position peaked at $596K in Q2 2020.
49 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2020.

Based on Zimmer Partners's 13F filing for Q3 2020, filed 16 Nov 2020.